Artelo Biosciences
1D
1W
1M
3M
YTD
1Y
5Y
ALL
Why Robinhood?
Robinhood gives you the tools you need to put your money in motion. You can buy or sell ARTL and other ETFs, options, and stocks.About ARTL
Artelo Biosciences, Inc. is a clinical stage biopharmaceutical company, which focuses on the development of therapeutics that target lipid-signaling pathways, including the endocannabinoid system. Its product candidate pipeline includes ART27.13-Synthetic Cannabinoid Agonist, ART26.12-FABP5 inhibitor, and ART12.11-Synthetic CBD Cocrystal.
CEOGregory D. Gorgas
CEOGregory D. Gorgas
Employees6
Employees6
HeadquartersSolana Beach, California
HeadquartersSolana Beach, California
Founded2011
Founded2011
Employees6
Employees6
ARTL Key Statistics
Market cap16.31M
Market cap16.31M
Price-Earnings ratio-1.33
Price-Earnings ratio-1.33
Dividend yield—
Dividend yield—
Average volume3.77M
Average volume3.77M
High today$28.46
High today$28.46
Low today$23.70
Low today$23.70
Open price$26.92
Open price$26.92
Volume191.22K
Volume191.22K
52 Week high$28.60
52 Week high$28.60
52 Week low$4.92
52 Week low$4.92
ARTL News
TipRanks 3d
Artelo Biosciences announces preclinical efficacy results of ART26.12Artelo Biosciences (ARTL) announced the presentation of preclinical data in an osteaoarthritis pain model on its lead fatty acid binding protein 5 nhibitor, ART...
People also own
Based on the portfolios of people who own ARTL. This list is generated using Robinhood data, and it’s not a recommendation.